REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin's innate glucosyltransferase in order to inhibit the toxin...Read more
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced updated data from its Phase 1/2 Study of ONCT-534 for the treatment of patients with relapsed or refractory metastatic Castration-Resistant Prostate Cancer...Read more
Vancouver, British Columbia – TheNewswire - 22 OCTOBER, 2024 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), is pleased to report that the final milestone in the Company’s Phase 2A Microdosing Depression Clinical Trial, the 6-month post treatment...Read more
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis The FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection...Read more
PRINCETON, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the U.S. Food and Drug Administration (FDA) has accepted its...Read more
Company to conduct a Phase 1 Drug-Drug Interaction Study Phase 2 filing on track for Q1 2025 SOUTH SAN FRANCISCO, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes...Read more
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| iRhythm Technologies | 13.07 21.05 | $75.18 |
| ZIVO Bioscience | 12.93 1,175.45 | $14.03 |
| Finch Therapeutics | 10.10 561.11 | $11.90 |
| Quest Diagnostics | 10.10 6.85 | $157.48 |
| Labcorp | 6.25 2.92 | $220.38 |
| IDEXX Laboratories | 5.88 1.30 | $459.26 |
| Alnylam Pharmaceuticals | 4.43 1.52 | $296.44 |
| Eli Lilly | 3.72 0.41 | $909.85 |
| argenx | 3.08 0.55 | $563.54 |
| Humana | 2.55 0.98 | $263.12 |
| Amgen | 2.41 0.76 | $319.15 |
| IGM Biosciences | 2.33 14.87 | $18.00 |
| Veradigm | 2.28 33.48 | $9.09 |
| HealthStream | 1.84 6.47 | $30.29 |
| Tarsus Pharmaceuticals | 1.83 5.02 | $38.28 |
| AbbVie | 1.83 0.98 | $188.37 |
| Kymera Therapeutics | 1.78 3.82 | $48.34 |
| Establishment Labs | 1.76 4.21 | $43.56 |
| Company | Volume | Last Trade |
|---|---|---|
| Ensysce Biosciences | 683,235,447 | $0.51 |
| ENDRA Life Sciences | 332,419,489 | $0.42 |
| Genprex | 140,471,036 | $2.61 |
| Aptevo Therapeutics | 125,314,889 | $0.30 |
| Sangamo Therapeutics | 59,261,077 | $1.28 |
| Vyome | 36,361,564 | $0.22 |
| BioVie | 30,024,179 | $3.42 |
| Cyclacel Pharmaceuticals | 26,018,245 | $1.51 |
| Walgreens Boots Alliance | 22,577,959 | $9.67 |
| Pfizer | 15,830,201 | $28.91 |
| Tonix Pharmaceuticals | 13,071,515 | $0.19 |
| TC Biopharm | 12,042,336 | $2.51 |
| Immunic | 9,961,388 | $1.40 |
| Applied DNA Sciences | 8,444,789 | $0.33 |
| GRI Bio | 7,346,063 | $0.96 |
| Werewolf Therapeutics | 7,145,131 | $3.62 |
| Geron | 7,019,779 | $4.00 |
| Allarity Therapeutics | 6,883,232 | $1.45 |
| CVS Health | 6,730,472 | $56.94 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
